GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, after nearly three ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Clearance of Lynkuet provides a new alternative to hormone-based treatment for hot flashes and sets up a market battle with Astellas Pharma’s Veozah.

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

For biopharma, reaching the right patients at the right time is essential for both clinical and commercial success. The right ...

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

The deal, which Novartis expects can “unlock multibillion-dollar opportunities” in the years ahead, hands the company a group ...

The preclinical drug from Vanqua Bio is designed to inhibit “C5aR1,” a part of the immune system that regulates inflammation.